1447308-16-8Relevant articles and documents
Orally available and efficacious α4β1/α4β7 integrin inhibitors
Xu, Ying-Zi,Smith, Jenifer L.,Semko, Christopher M.,Rossiter, Kassandra I.,Fukuda, Juri Y.,Dappen, Michael S.,Quincy, David A.,Konradi, Andrei W.,Mao, Wenxian,Welch, Brent,Dreyer, Mark L.,Samant, Bhushan,Zhang, Hongbin,Lugar, Judevin,Liao, Zhenmei,Henschel, Carrol,Petersen, Eric,Vandevert, Christopher,Shoemaker, Mark,Wehner, Nancy,Mutter, Linda,Shopp, George,Krimm, Michael,Chen, Linda,Wipke, Brian,Dofiles, Lilibeth,Gallager, Ian,Sauer, John-Michael,Messersmith, Elizabeth K.,Pleiss, Michael A.,Bard, Frederique,Yednock, Ted A.
, p. 4370 - 4373 (2013/07/26)
A series of potent α4β1/α4β7 integrin inhibitors is reported, including an inhibitor 12d with remarkable oral exposure and efficacy in rat models of rheumatoid arthritis and Crohn's disease.